Tulane National Primate Research Center

杜兰国家灵长类动物研究中心

• 批准号: 8296351
• 负责人: Benjamin Paul Sachs
• 金额: $ 790.12万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-05-09 至 2013-06-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8296351
• 关键词: Acquired Immunodeficiency Syndrome; Appointment; Area; Award; Budgets; Collaborations; Communicable Diseases; Development; Disease; Extramural Research Facilities Construction Project; Faculty; Funding; Future; Grant; Growth; Health; Individual; Infection; Institution; Laboratories; Link; Lyme Disease; Mission; Pathogenesis; Primates; Request for Applications; Research; Research Personnel; Research Project Grants; Resources; Rest; Time; Training and Education; Tuberculosis; United States National Institutes of Health; Universities; base; biodefense; biosafety level 3 facility; gene therapy; multidisciplinary; novel strategies; operation; programs; transmission process; vaccine development

This application requests funding for the Tulane National Primate Research Center (TNPRC) for the fiveyear period beginning May 1, 2008 through April 30, 2013. Funds will be used to support the administration, operations, veterinary resources, scientific research resources and education and training mission of the Center. Additional funds to support pilot research projects and colony-health-related research resource projects are also requested. For nearly three decades the main focus of the TNPRC research program has been infectious disease. This will continue. In addition, a significant program in gene therapy that is tightly linked to the Center for Gene Therapy at Tulane has developed over the last five years. The major areas of funding for the infectious disease program are currently AIDS, Lyme disease and biodefense-related agents; there are also areas under development, such as tuberculosis. These are multidisciplinary studies involving investigators in multiple Divisions at the TNPRC and collaborators outside the Center. The studies cover the spectrum from transmission and pathogenesis to development of vaccine strategies and chemotherapeutic treatments. The gene therapy program provides an important link to the rest of the University, allows for novel approaches to the treatment of many types of disease and imparts additional diversity to our research program. The period since the last submission of the TNPRC base grant has been a time of significant growth and improvement at the Center. Total sponsored funding has increased dramatically and individual, investigator initiated awards now exceed total awards at the time of the last base grant submission. We are currently at the beginning of a major expansion of our facilities in support of the growing research program. The total construction budget for current projects is in excess of $50M and will add approximately 80,000sf to the facility. The expansion is funded by numerous NIH construction awards (C06, UC6) and private funds. Of particular note is the Regional Biosafety Laboratory. This is a BSL-3 facility that will focus on biodefense and emerging infections in support of the NIH biodefense research agenda. Based on the progress in the last five years we are very optimistic about the future. Strengths on which we can capitalize include significant funded renovation and expansion projects, a research focus (infectious diseases and gene therapy) that matches NIH and national priorities, faculty appointments, strong and diverse research resources, a talented and dedicated staff, excellent interactions and collaborations with area universities and an outstanding relationship with our host institution and state and federal legislators.

该申请要求为五年 从2008年5月1日到2013年4月30日开始。资金将用于支持政府， 运营，兽医资源，科学研究资源以及教育和培训使命 中心。额外的资金支持试点研究项目和殖民地健康相关的研究资源 还要求项目。 近三十年来，TNPRC研究计划的主要重点一直是传染病。 这将继续。此外，基因疗法的重要计划与中心紧密相关 在过去五年中，图兰基因疗法发展。用于的主要资金领域 传染病计划目前是艾滋病，莱姆病和与生物反应相关的药物；也有 正在开发的地区，例如结核病。这些是涉及研究人员参与的多学科研究 TNPRC的多个部门和中心外的合作者。研究涵盖了来自 疫苗策略和化学治疗的发展传播和发病机理。这 基因治疗计划提供了与大学其他成员的重要联系，允许采用新颖的方法 治疗多种类型的疾病并为我们的研究计划提供了额外的多样性。 自TNPRC基础赠款上次提交以来的时期是一个显着增长的时期， 中心的改进。总赞助资金急剧增加，个人，调查员 现在，在上次基本赠款提交时，发起奖项超过了总奖项。我们目前在 我们设施的重大扩展开始，以支持不断增长的研究计划。总计 当前项目的施工预算超过5000万美元，将增加约80,000SF 设施。该扩展由许多NIH建筑奖（C06，UC6）和私人资金提供资金。的 特别注意的是区域生物安全实验室。这是一个BSL-3设施，将重点放在生物形式和 新兴的感染支持NIH生物防腐研究议程。 根据过去五年中的进步，我们对未来非常乐观。优势 我们可以将资本化包括大量资助的翻新和扩展项目，研究重点（感染力 疾病和基因疗法）与NIH和国家优先事项，任命强大的疾病和基因疗法相匹配 多样化的研究资源，有才华和敬业的员工，出色的互动以及与 地区大学以及与我们的东道机构，州和联邦立法者的良好关系。